Valuation: Scholar Rock Holding Corporation

Market Cap 6.78B 5.94B 5.49B 5.07B 9.61B 649B 9.8B 65.98B 25.64B 318B 25.45B 24.89B 1,102B P/E 2026 *
-17.8x
P/E 2027 * -22.2x
Enterprise Value 6.48B 5.68B 5.24B 4.85B 9.18B 620B 9.37B 63.04B 24.49B 303B 24.32B 23.78B 1,053B EV / Sales 2026 *
994x
EV / Sales 2027 * 43x
Free-Float
99.22%
Yield 2026 *
-
Yield 2027 * -
1 day-0.94%
1 week+6.04%
Current month+1.87%
1 month+27.92%
3 months+12.08%
6 months+34.46%
Current year+27.20%
1 week 51.32
Extreme 51.3195
57.8
1 month 43.23
Extreme 43.23
57.8
Current year 38.75
Extreme 38.75
57.8
1 year 27.07
Extreme 27.07
57.8
3 years 5.93
Extreme 5.93
57.8
5 years 4.32
Extreme 4.325
57.8
10 years 4.32
Extreme 4.325
70
Manager TitleAgeSince
Chief Executive Officer 59 26/04/2025
Director of Finance/CFO 62 26/04/2025
Chief Operating Officer 58 26/04/2025
Director TitleAgeSince
Chairman 59 30/06/2017
Director/Board Member 53 31/07/2014
Director/Board Member 78 30/09/2016
Date Insider Type Main position Quantity % Market Cap.
06-30Sell

Director

-3,053 0.0027%
06-30
ARCH Venture Partners LLC
OtherCompany 0 0%
06-30Sell

Director

-2,544 0.0022%
Change 5-day change 1-year change 3-year change Capi.($)
-0.94%+6.04%+63.64%+662.31% 6.78B
-1.53%-1.43%+71.67%+129.70% 57.72B
-2.45%-7.32%+65.23%+83.15% 52.65B
+3.27%+8.91%+21.21%+471.23% 24.46B
-0.81%+0.52%-15.01%-12.47% 23.84B
-3.05%+3.06%+42.36%-5.66% 19.28B
-0.24%+5.11%+38.76%-25.95% 17.8B
+2.34%+14.18%+220.96%+380.99% 17.29B
-6.73%+9.90%+36.04% - 15.28B
-1.70%+3.98%+28.96%+194.23% 14.35B
Average -1.18%+4.96%+57.38%+208.61% 24.95B
Weighted average by Cap. -1.25%+2.71%+57.95%+155.37%

Financials

2026 *2027 *
Net sales 6.51M 5.71M 5.27M 4.87M 9.24M 624M 9.42M 63.39M 24.63M 305M 24.45M 23.92M 1.06B 149M 131M 121M 112M 212M 14.31B 216M 1.46B 565M 7B 561M 549M 24.31B
Net income -410M -359M -332M -307M -581M -39.23B -593M -3.99B -1.55B -19.2B -1.54B -1.5B -66.64B -356M -313M -289M -267M -505M -34.12B -515M -3.47B -1.35B -16.7B -1.34B -1.31B -57.96B
Net Debt -302M -265M -245M -226M -428M -28.92B -437M -2.94B -1.14B -14.15B -1.13B -1.11B -49.13B -356M -312M -288M -266M -504M -34.05B -514M -3.46B -1.34B -16.66B -1.34B -1.31B -57.84B
Logo Scholar Rock Holding Corporation
Scholar Rock Holding Corporation is a biopharmaceutical company. The Company focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe and debilitating neuromuscular diseases. Its pipeline product candidates include apitegromab, a subcutaneous formulation of apitegromab, and SRK-439. The Apitegromab is an investigational fully human, intravenously administered monoclonal antibody designed to inhibit myostatin activation by selectively binding the pro- and latent forms of myostatin in the skeletal muscle. The SRK-439, is an investigational, subcutaneously administered fully human anti-pro/latent myostatin antibody that has high inhibitory potency while maintaining selectivity towards myostatin. Its early-stage pipeline includes additional programs for the treatment of patients with rare, severe, and debilitating neuromuscular diseases.
Employees
289
Date Price Change Volume
08/07/26 US$56.03 -0.94% 757,634
07/07/26 US$56.56 +2.17% 1,144,016
06/07/26 US$55.36 +0.87% 1,182,409
02/07/26 US$54.88 +3.86% 1,726,056
01/07/26 US$52.84 -3.93% 1,304,387
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
56.56USD
Average target price
59.31USD
Spread / Average Target
+4.87%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SRRK Stock